학술논문

Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; JUN 1 2023, 41 16, 1p. Supplement: S
Subject
Language
English
ISSN
15277755